Phathom Pharmaceuticals Inc
$ 17.56
-0.57%
26 Dec - close price
- Market Cap 1,249,191,000 USD
- Current Price $ 17.56
- High / Low $ 17.73 / 17.36
- Stock P/E N/A
- Book Value -5.95
- EPS -3.76
- Next Earning Report 2026-03-03
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.43 %
- ROE -34.89 %
- 52 Week High 18.31
- 52 Week Low 2.21
About
Phathom Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company headquartered in Florham Park, New Jersey, dedicated to developing and commercializing innovative therapies targeting gastrointestinal disorders. The company boasts a promising pipeline of treatments designed to address significant unmet medical needs, particularly those affecting patients with severe gastrointestinal conditions. With its emphasis on rigorous clinical development and the potential for upcoming product launches, Phathom is strategically positioned for substantial growth, making it an attractive investment opportunity for institutional investors interested in the evolving biopharmaceutical landscape.
Analyst Target Price
$22.90
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-30 | 2025-08-07 | 2025-05-07 | 2025-03-05 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-03-07 | 2023-11-09 | 2023-08-10 | 2023-05-10 | 2023-02-28 |
| Reported EPS | -0.15 | -0.79 | -1.07 | -1.05 | -1.32 | -1.56 | -1.42 | -1.39 | -0.76 | -0.84 | -0.89 | -1.33 |
| Estimated EPS | -0.47 | -0.91 | -1.066 | -1.08 | -1.49 | -1.38 | -1.31 | -1.08 | -0.89 | -0.98 | -1.26 | -1.35 |
| Surprise | 0.32 | 0.12 | -0.004 | 0.03 | 0.17 | -0.18 | -0.11 | -0.31 | 0.13 | 0.14 | 0.37 | 0.02 |
| Surprise Percentage | 68.0851% | 13.1868% | -0.3752% | 2.7778% | 11.4094% | -13.0435% | -8.3969% | -28.7037% | 14.6067% | 14.2857% | 29.3651% | 1.4815% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-03 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.2876 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PHAT
2025-12-22 15:10:19
Phathom Pharmaceuticals (PHAT) stock has reached a 52-week high of $17.87, reflecting a 130.35% increase over the past year and indicating growing investor confidence. The company also reported strong Q3 2025 earnings for Voquezna and initiated a Phase 2 trial for its use in eosinophilic esophagitis, leading analysts to raise their price targets.
2025-12-18 16:10:00
Phathom Pharmaceuticals (NASDAQ:PHAT) hit a new 52-week high of $16.60, with shares up approximately 3.6% during Thursday's trading. The company reported beating Q3 earnings estimates, and analysts have a "Moderate Buy" consensus rating with a $21.00 average price target. Despite strong institutional ownership, Phathom remains unprofitable with expected negative EPS for the current year.
2025-12-17 18:10:00
Phathom Pharmaceuticals (NASDAQ:PHAT) boasts a high price-to-sales (P/S) ratio of 7.2x, significantly above the pharmaceutical industry average, which suggests investor optimism. This elevated P/S ratio is driven by strong revenue growth and analyst forecasts predicting 66% annual revenue growth over the next three years, substantially outperforming the broader industry. While a high P/S can indicate overvaluation, in Phathom's case, it reflects market confidence in its future revenue potential.
2025-12-17 03:09:35
Phathom Pharmaceuticals (PHAT) is gaining significant investor attention due to a bullish analyst rating, better-than-expected quarterly earnings, an increased revenue forecast for 2025, and advancements in its VOQUEZNA clinical trials. Despite its shares more than doubling this year, the company still trades at a substantial discount to analyst targets, with a fair value estimated at $22.90 against a $15.24 last close, suggesting potential for further upside if growth assumptions hold. However, risks such as reimbursement challenges or trial setbacks for VOQUEZNA could impact its growth trajectory.
2025-12-15 16:09:21
Phathom Pharmaceuticals (PHAT) recently received a "Strong Buy" rating after exceeding Q3 2025 forecasts, raising revenue guidance, and advancing Voquezna for GERD. The company is also expanding Voquezna into new indications like eosinophilic esophagitis, further diversifying its gastrointestinal franchise. While these developments strengthen the near-term commercialization story, the primary investment thesis remains Voquezna's ability to drive profitability and offset cash burn before generic competition arrives.
2025-12-14 14:09:32
Raymond James Financial has initiated coverage on Phathom Pharmaceuticals (NASDAQ:PHAT) with a "strong-buy" rating and a $28 price target, indicating a 92% upside. Analyst consensus for PHAT is a "Moderate Buy" with an average target of $21, reflecting a range of views from various firms. The company reported strong institutional ownership, favorable quarterly earnings, and significant revenue, with recent buys by Millennium Management and Frazier Life Sciences.
